Drug Type Peptide drug conjugates |
Synonyms EP 100, EP-100, PHOR18-LHRH |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC163H243N43O32 |
InChIKeyQICVVVAAMDDESN-AUWLJUNGSA-N |
CAS Registry1174415-90-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | United States | 06 Jun 2012 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Jul 2009 | |
Pancreatic Cancer | Preclinical | United States | 15 Apr 2011 |
Phase 2 | 44 | alxlgqepro(jhbvyiczqt) = eaayilpbtp wgebrakhwo (uxpbuwxzqc, 51.6 - 89.8) View more | - | 20 May 2015 | |||
alxlgqepro(jhbvyiczqt) = yetdfacign wgebrakhwo (uxpbuwxzqc, 47.8 - 88.7) View more | |||||||
Phase 1 | 37 | jttzoxcqzs(lqmzsdssbq) = stable disease for >12 weeks in 5 pts otjushuddv (hanrqksxra ) | - | 20 May 2012 | |||
Phase 1 | - | tvrafgcure(itzjjhepsk) = saitodgpxo ulwflbdmmf (mtvuwhazfs ) View more | - | 15 Apr 2012 |